{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:24:05Z","timestamp":1793129045117,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-94291-9","type":"journal-article","created":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T22:13:17Z","timestamp":1742595197000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Reducing toxicity and enhancing efficacy of doxorubicin by liposomal doxorubicin and aprepitant in breast cancer"],"prefix":"10.1038","volume":"15","author":[{"given":"Atefeh","family":"Ghahremanloo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahareh","family":"Erfani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fereshteh","family":"Asgharzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saeide","family":"Mansoori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Gheybi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Isaac","family":"Hashemy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"key":"94291_CR1","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/1994764","volume":"2021","author":"YN Zhang","year":"2021","unstructured":"Zhang, Y. N., Xia, K. R., Li, C. Y., Wei, B. L. & Zhang, B. Review of breast cancer pathologigcal image processing. Biomed. Res. Int. 2021, 1994764. https:\/\/doi.org\/10.1155\/2021\/1994764 (2021).","journal-title":"Biomed. Res. Int."},{"key":"94291_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12968\/hmed.2021.0459","volume":"83","author":"C Katsura","year":"2022","unstructured":"Katsura, C., Ogunmwonyi, I., Kankam, H. K. N. & Saha, S. Breast cancer: presentation, investigation and management. Br. J. Hosp. Med. 83, 1\u20137. https:\/\/doi.org\/10.12968\/hmed.2021.0459 (2022).","journal-title":"Br. J. Hosp. Med."},{"key":"94291_CR3","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40659-017-0140-9","volume":"50","author":"M Akram","year":"2017","unstructured":"Akram, M., Iqbal, M., Daniyal, M. & Khan, A. U. Awareness and current knowledge of breast cancer. Biol. Res. 50, 33. https:\/\/doi.org\/10.1186\/s40659-017-0140-9 (2017).","journal-title":"Biol. Res."},{"key":"94291_CR4","unstructured":"World Health Organization. Breast cancer. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/breast-cancer (2021)."},{"key":"94291_CR5","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/cac2.12358","volume":"42","author":"R Hong","year":"2022","unstructured":"Hong, R. & Xu, B. Breast cancer: an up-to-date review and future perspectives. Cancer Commun. (Lond) 42, 913\u2013936. https:\/\/doi.org\/10.1002\/cac2.12358 (2022).","journal-title":"Cancer Commun. (Lond)"},{"key":"94291_CR6","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nrclinonc.2010.192","volume":"7","author":"L Hutchinson","year":"2010","unstructured":"Hutchinson, L. Challenges, controversies, breakthroughs. Nat. Rev. Clin. Oncol. 7, 669\u2013670. https:\/\/doi.org\/10.1038\/nrclinonc.2010.192 (2010).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"94291_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.12691\/jcrt-7-1-3","volume":"7","author":"A Alghorabi","year":"2019","unstructured":"Alghorabi, A., Kabel, A. & Abdelmaboud, M. Doxorubicin: Insights into dynamics, clinical uses and adverse effects. J. Cancer Res. Treat. 7, 17\u201320. https:\/\/doi.org\/10.12691\/jcrt-7-1-3 (2019).","journal-title":"J. Cancer Res. Treat."},{"key":"94291_CR8","doi-asserted-by":"publisher","first-page":"131","DOI":"10.2147\/bctt.S170239","volume":"10","author":"YL Franco","year":"2018","unstructured":"Franco, Y. L., Vaidya, T. R. & Ait-Oudhia, S. Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer. Breast Cancer (Dove Med Press) 10, 131\u2013141. https:\/\/doi.org\/10.2147\/bctt.S170239 (2018).","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"94291_CR9","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/s1734-1140(13)71021-1","volume":"65","author":"GS Wu","year":"2013","unstructured":"Wu, G. S. et al. Synergistic anti-cancer activity of the combination of dihydroartemisinin and doxorubicin in breast cancer cells. Pharmacol. Rep. 65, 453\u2013459. https:\/\/doi.org\/10.1016\/s1734-1140(13)71021-1 (2013).","journal-title":"Pharmacol. Rep."},{"key":"94291_CR10","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41419-023-05972-0","volume":"14","author":"Y Liang","year":"2023","unstructured":"Liang, Y. et al. HSPB1 facilitates chemoresistance through inhibiting ferroptotic cancer cell death and regulating NF-\u03baB signaling pathway in breast cancer. Cell Death Dis. 14, 434. https:\/\/doi.org\/10.1038\/s41419-023-05972-0 (2023).","journal-title":"Cell Death Dis."},{"key":"94291_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2023.1271420","volume":"11","author":"W Zeng","year":"2023","unstructured":"Zeng, W. et al. Advances in doxorubicin-based nano-drug delivery system in triple negative breast cancer. Front. Bioeng. Biotechnol. 11, 1271420. https:\/\/doi.org\/10.3389\/fbioe.2023.1271420 (2023).","journal-title":"Front. Bioeng. Biotechnol."},{"key":"94291_CR12","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","volume":"42","author":"A Gabizon","year":"2003","unstructured":"Gabizon, A., Shmeeda, H. & Barenholz, Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin. Pharmacokinet. 42, 419\u2013436. https:\/\/doi.org\/10.2165\/00003088-200342050-00002 (2003).","journal-title":"Clin. Pharmacokinet."},{"key":"94291_CR13","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1093\/annonc\/mdh097","volume":"15","author":"ME O\u2019Brien","year":"2004","unstructured":"O\u2019Brien, M. E. et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann. Oncol. 15, 440\u2013449. https:\/\/doi.org\/10.1093\/annonc\/mdh097 (2004).","journal-title":"Ann. Oncol."},{"key":"94291_CR14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jconrel.2012.03.020","volume":"160","author":"Y Barenholz","year":"2012","unstructured":"Barenholz, Y. Doxil\u00ae\u2014The first FDA-approved nano-drug: Lessons learned. J. Control. Release 160, 117\u2013134. https:\/\/doi.org\/10.1016\/j.jconrel.2012.03.020 (2012).","journal-title":"J. Control. Release"},{"key":"94291_CR15","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.drup.2016.10.003","volume":"29","author":"AA Gabizon","year":"2016","unstructured":"Gabizon, A. A., Patil, Y. & La-Beck, N. M. New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy. Drug Resist. Updates 29, 90\u2013106. https:\/\/doi.org\/10.1016\/j.drup.2016.10.003 (2016).","journal-title":"Drug Resist. Updates"},{"key":"94291_CR16","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jconrel.2017.07.010","volume":"261","author":"A F\u00fcredi","year":"2017","unstructured":"F\u00fcredi, A. et al. Pegylated liposomal formulation of doxorubicin overcomes drug resistance in a genetically engineered mouse model of breast cancer. J. Control. Release 261, 287\u2013296. https:\/\/doi.org\/10.1016\/j.jconrel.2017.07.010 (2017).","journal-title":"J. Control. Release"},{"key":"94291_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.746114","volume":"12","author":"W Hu","year":"2021","unstructured":"Hu, W. et al. Pegylated liposomal doxorubicin versus epirubicin as adjuvant therapy for stage I\u2013III breast cancer. Front. Genet. 12, 746114. https:\/\/doi.org\/10.3389\/fgene.2021.746114 (2021).","journal-title":"Front. Genet."},{"key":"94291_CR18","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.44837","volume":"15","author":"M Alhaja","year":"2023","unstructured":"Alhaja, M., Chen, S., Chin, A. C., Schulte, B. & Legasto, C. S. Cardiac safety of pegylated liposomal doxorubicin after conventional doxorubicin exposure in patients with sarcoma and breast cancer. Cureus 15, e44837. https:\/\/doi.org\/10.7759\/cureus.44837 (2023).","journal-title":"Cureus"},{"key":"94291_CR19","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1471-2407-10-2","volume":"10","author":"J Huober","year":"2010","unstructured":"Huober, J. et al. A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer. BMC Cancer 10, 2. https:\/\/doi.org\/10.1186\/1471-2407-10-2 (2010).","journal-title":"BMC Cancer"},{"key":"94291_CR20","doi-asserted-by":"publisher","first-page":"408","DOI":"10.2174\/1389557519666191112152642","volume":"20","author":"M Mu\u00f1oz","year":"2020","unstructured":"Mu\u00f1oz, M., Rosso, M. & Cove\u00f1as, R. Triple negative breast cancer: how neurokinin-1 receptor antagonists could be used as a new therapeutic approach. Mini Rev. Med. Chem. 20, 408\u2013417. https:\/\/doi.org\/10.2174\/1389557519666191112152642 (2020).","journal-title":"Mini Rev. Med. Chem."},{"key":"94291_CR21","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s11033-019-04599-9","volume":"46","author":"M Davoodian","year":"2019","unstructured":"Davoodian, M. et al. Evaluation of serum level of substance P and tissue distribution of NK-1 receptor in breast cancer. Mol. Biol. Rep. 46, 1285\u20131293. https:\/\/doi.org\/10.1007\/s11033-019-04599-9 (2019).","journal-title":"Mol. Biol. Rep."},{"key":"94291_CR22","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/1959270","volume":"2016","author":"P Robinson","year":"2016","unstructured":"Robinson, P. et al. Substance P receptor signaling mediates doxorubicin-induced cardiomyocyte apoptosis and triple-negative breast cancer chemoresistance. Biomed. Res. Int. 2016, 1959270. https:\/\/doi.org\/10.1155\/2016\/1959270 (2016).","journal-title":"Biomed. Res. Int."},{"key":"94291_CR23","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/1383878","volume":"2021","author":"A Ghahremanloo","year":"2021","unstructured":"Ghahremanloo, A., Javid, H., Afshari, A. R. & Hashemy, S. I. Investigation of the role of neurokinin-1 receptor inhibition using aprepitant in the apoptotic cell death through PI3K\/Akt\/NF-\u03baB signal transduction pathways in colon cancer cells. Biomed. Res. Int. 2021, 1383878. https:\/\/doi.org\/10.1155\/2021\/1383878 (2021).","journal-title":"Biomed. Res. Int."},{"key":"94291_CR24","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1007\/s11033-021-06928-3","volume":"49","author":"M Mozafari","year":"2022","unstructured":"Mozafari, M., Ebrahimi, S., Darban, R. A. & Hashemy, S. I. Potential in vitro therapeutic effects of targeting SP\/NK1R system in cervical cancer. Mol. Biol. Rep. 49, 1067\u20131076. https:\/\/doi.org\/10.1007\/s11033-021-06928-3 (2022).","journal-title":"Mol. Biol. Rep."},{"key":"94291_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13071732","author":"A Legi","year":"2021","unstructured":"Legi, A., Rodriguez, E., Eckols, T. K., Mistry, C. & Robinson, P. Substance P antagonism prevents chemotherapy-induced cardiotoxicity. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers13071732 (2021).","journal-title":"Cancers (Basel)"},{"key":"94291_CR26","doi-asserted-by":"publisher","first-page":"7796","DOI":"10.1007\/s12010-023-04495-w","volume":"195","author":"S Ebrahimi","year":"2023","unstructured":"Ebrahimi, S. et al. The in vitro pro-inflammatory functions of the SP\/NK1R system in prostate cancer: a focus on nuclear factor-kappa B (NF-\u03baB) and its pro-inflammatory target genes. Appl. Biochem. Biotechnol. 195, 7796\u20137807. https:\/\/doi.org\/10.1007\/s12010-023-04495-w (2023).","journal-title":"Appl. Biochem. Biotechnol."},{"key":"94291_CR27","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1186\/s12885-023-10954-8","volume":"23","author":"X Cao","year":"2023","unstructured":"Cao, X. et al. Aprepitant inhibits the development and metastasis of gallbladder cancer via ROS and MAPK activation. BMC Cancer 23, 471. https:\/\/doi.org\/10.1186\/s12885-023-10954-8 (2023).","journal-title":"BMC Cancer"},{"key":"94291_CR28","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1634\/theoncologist.2014-0229","volume":"20","author":"M Aapro","year":"2015","unstructured":"Aapro, M. et al. Aprepitant and fosaprepitant: a 10-year review of efficacy and safety. Oncologist 20, 450\u2013458. https:\/\/doi.org\/10.1634\/theoncologist.2014-0229 (2015).","journal-title":"Oncologist"},{"key":"94291_CR29","doi-asserted-by":"publisher","first-page":"9307","DOI":"10.1007\/s11033-022-07771-w","volume":"49","author":"M Momen Razmgah","year":"2022","unstructured":"Momen Razmgah, M. et al. The effect of substance P and its specific antagonist (aprepitant) on the expression of MMP-2, MMP-9, VEGF, and VEGFR in ovarian cancer cells. Mol. Biol. Rep. 49, 9307\u20139314. https:\/\/doi.org\/10.1007\/s11033-022-07771-w (2022).","journal-title":"Mol. Biol. Rep."},{"key":"94291_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2024.123210","volume":"359","author":"AA Gomaa","year":"2024","unstructured":"Gomaa, A. A., Abdallah, D. M., El-Abhar, H. S. & El-Mokadem, B. M. Repurposing Aprepitant: Can it protect against doxorubicin-induced Chemobrain beyond its antiemetic role?. Life Sci. 359, 123210. https:\/\/doi.org\/10.1016\/j.lfs.2024.123210 (2024).","journal-title":"Life Sci."},{"key":"94291_CR31","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1016\/j.jhep.2013.12.024","volume":"60","author":"M Berger","year":"2014","unstructured":"Berger, M. et al. Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo. J. Hepatol. 60, 985\u2013994. https:\/\/doi.org\/10.1016\/j.jhep.2013.12.024 (2014).","journal-title":"J. Hepatol."},{"key":"94291_CR32","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1021\/acs.molpharmaceut.6b01006","volume":"14","author":"SH Alavizadeh","year":"2017","unstructured":"Alavizadeh, S. H. et al. Therapeutic efficacy of cisplatin thermosensitive liposomes upon mild hyperthermia in C26 tumor bearing BALB\/c mice. Mol. Pharm. 14, 712\u2013721. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.6b01006 (2017).","journal-title":"Mol. Pharm."},{"key":"94291_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtemb.2023.127291","volume":"80","author":"F Gheybi","year":"2023","unstructured":"Gheybi, F. et al. Liposomal silymarin anti-oxidative and anti-apoptotic features in lung cells: An implication in cadmium toxicity. J. Trace Elem. Med. Biol. 80, 127291. https:\/\/doi.org\/10.1016\/j.jtemb.2023.127291 (2023).","journal-title":"J. Trace Elem. Med. Biol."},{"key":"94291_CR34","doi-asserted-by":"publisher","first-page":"760","DOI":"10.7150\/ijbs.65258","volume":"18","author":"CY Kong","year":"2022","unstructured":"Kong, C. Y. et al. Underlying the mechanisms of doxorubicin-induced acute cardiotoxicity: oxidative stress and cell death. Int. J. Biol. Sci. 18, 760\u2013770. https:\/\/doi.org\/10.7150\/ijbs.65258 (2022).","journal-title":"Int. J. Biol. Sci."},{"key":"94291_CR35","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1124\/dmd.32.8.794","volume":"32","author":"SN Hilmer","year":"2004","unstructured":"Hilmer, S. N., Cogger, V. C., Muller, M. & Le Couteur, D. G. The hepatic pharmacokinetics of doxorubicin and liposomal doxorubicin. Drug Metab. Dispos. 32, 794\u2013799. https:\/\/doi.org\/10.1124\/dmd.32.8.794 (2004).","journal-title":"Drug Metab. Dispos."},{"key":"94291_CR36","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33588","author":"J Ferlay","year":"2021","unstructured":"Ferlay, J. et al. Cancer statistics for the year 2020: An overview. Int. J. Cancer https:\/\/doi.org\/10.1002\/ijc.33588 (2021).","journal-title":"Int. J. Cancer"},{"key":"94291_CR37","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12645-023-00169-8","volume":"14","author":"A Askarizadeh","year":"2023","unstructured":"Askarizadeh, A. et al. Doxorubicin-loaded liposomes surface engineered with the matrix metalloproteinase-2 cleavable polyethylene glycol conjugate for cancer therapy. Cancer Nanotechnol. 14, 18. https:\/\/doi.org\/10.1186\/s12645-023-00169-8 (2023).","journal-title":"Cancer Nanotechnol."},{"key":"94291_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpx.2023.100214","volume":"6","author":"M Doagooyan","year":"2023","unstructured":"Doagooyan, M. et al. Anti-tumor activity of silymarin nanoliposomes in combination with iron: In vitro and in vivo study. Int. J. Pharm. X 6, 100214. https:\/\/doi.org\/10.1016\/j.ijpx.2023.100214 (2023).","journal-title":"Int. J. Pharm. X"},{"key":"94291_CR39","doi-asserted-by":"publisher","first-page":"166","DOI":"10.7150\/ntno.31164","volume":"3","author":"S Ray","year":"2019","unstructured":"Ray, S. et al. Magnetic heating stimulated cargo release with dose control using multifunctional MR and thermosensitive liposome. Nanotheranostics 3, 166\u2013178. https:\/\/doi.org\/10.7150\/ntno.31164 (2019).","journal-title":"Nanotheranostics"},{"key":"94291_CR40","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.ijpharm.2016.03.060","volume":"505","author":"J Akhtari","year":"2016","unstructured":"Akhtari, J. et al. Targeting, bio distributive and tumor growth inhibiting characterization of anti-HER2 affibody coupling to liposomal doxorubicin using BALB\/c mice bearing TUBO tumors. Int. J. Pharm. 505, 89\u201395. https:\/\/doi.org\/10.1016\/j.ijpharm.2016.03.060 (2016).","journal-title":"Int. J. Pharm."},{"key":"94291_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2021.102351","volume":"62","author":"SM Haftcheshmeh","year":"2021","unstructured":"Haftcheshmeh, S. M. et al. Liposomal doxorubicin targeting mitochondria: A novel formulation to enhance anti-tumor effects of Doxil\u00ae in vitro and in vivo. J. Drug Deliv. Sci. Technol. 62, 102351. https:\/\/doi.org\/10.1016\/j.jddst.2021.102351 (2021).","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"94291_CR42","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ejps.2016.03.009","volume":"86","author":"M Zahmatkeshan","year":"2016","unstructured":"Zahmatkeshan, M., Gheybi, F., Rezayat, S. M. & Jaafari, M. R. Improved drug delivery and therapeutic efficacy of PEgylated liposomal doxorubicin by targeting anti-HER2 peptide in murine breast tumor model. Eur. J. Pharm. Sci. 86, 125\u2013135. https:\/\/doi.org\/10.1016\/j.ejps.2016.03.009 (2016).","journal-title":"Eur. J. Pharm. Sci."},{"key":"94291_CR43","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1002\/biof.1953","volume":"49","author":"S Ebrahimi","year":"2023","unstructured":"Ebrahimi, S. et al. The in vitro anti-cancer synergy of neurokinin-1 receptor antagonist, aprepitant, and 5-aminolevulinic acid in glioblastoma. BioFactors (Oxford, England) 49, 900\u2013911. https:\/\/doi.org\/10.1002\/biof.1953 (2023).","journal-title":"BioFactors (Oxford, England)"},{"key":"94291_CR44","doi-asserted-by":"crossref","unstructured":"Ghahremanloo, A. et al. Synergistic anticancer effects of liposomal doxorubicin and aprepitant combination therapy in breast cancer: Preclinical insights and therapeutic potential. J. Drug Deliv. Sci. Technol. 105, 106620 (2025).","DOI":"10.1016\/j.jddst.2025.106620"},{"key":"94291_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15071920","author":"H Dorostkar","year":"2023","unstructured":"Dorostkar, H. et al. Reduction of doxorubicin-induced cardiotoxicity by co-administration of smart liposomal doxorubicin and free quercetin: In vitro and in vivo studies. Pharmaceutics https:\/\/doi.org\/10.3390\/pharmaceutics15071920 (2023).","journal-title":"Pharmaceutics"},{"key":"94291_CR46","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1021\/mp200439z","volume":"9","author":"SR Paliwal","year":"2012","unstructured":"Paliwal, S. R. et al. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy. Mol. Pharm. 9, 176\u2013186. https:\/\/doi.org\/10.1021\/mp200439z (2012).","journal-title":"Mol. Pharm."},{"key":"94291_CR47","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0133569","volume":"10","author":"M Xing","year":"2015","unstructured":"Xing, M., Yan, F., Yu, S. & Shen, P. Efficacy and cardiotoxicity of liposomal doxorubicin-based chemotherapy in advanced breast cancer: a meta-analysis of ten randomized controlled trials. PLoS One 10, e0133569. https:\/\/doi.org\/10.1371\/journal.pone.0133569 (2015).","journal-title":"PLoS One"},{"key":"94291_CR48","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13104-018-3260-6","volume":"11","author":"C Stark","year":"2018","unstructured":"Stark, C., Taimen, P., Savunen, T. & Koskenvuo, J. Pegylated and liposomal doxorubicin is associated with high mortality and causes limited cardiotoxicity in mice. BMC Res. Notes 11, 148. https:\/\/doi.org\/10.1186\/s13104-018-3260-6 (2018).","journal-title":"BMC Res. Notes"},{"key":"94291_CR49","doi-asserted-by":"publisher","first-page":"5875","DOI":"10.1007\/s00210-024-02996-x","volume":"397","author":"S Zarei Shandiz","year":"2024","unstructured":"Zarei Shandiz, S., Assaran Darban, R., Javid, H., Ghahremanloo, A. & Hashemy, S. I. The effect of SP\/NK1R on expression and activity of glutaredoxin and thioredoxin proteins in prostate cancer cells. Naunyn-Schmiedeberg\u2019s Arch. Pharmacol. 397, 5875\u20135882. https:\/\/doi.org\/10.1007\/s00210-024-02996-x (2024).","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"94291_CR50","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s10989-022-10399-w","volume":"28","author":"H Javid","year":"2022","unstructured":"Javid, H., Ghahremanloo, A., Afshari, A. R., Salek, R. & Hashemy, S. I. The emerging role of neurokinin-1 receptor blockade using aprepitant in the redox system of esophageal squamous cell carcinoma. Int. J. Peptide Res. Ther. 28, 89. https:\/\/doi.org\/10.1007\/s10989-022-10399-w (2022).","journal-title":"Int. J. Peptide Res. Ther."},{"key":"94291_CR51","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/978-1-60761-609-2_14","volume-title":"Cancer Nanotechnology: Methods and Protocols","author":"G Niu","year":"2010","unstructured":"Niu, G., Cogburn, B. & Hughes, J. In Cancer Nanotechnology: Methods and Protocols (eds Grobmyer, S. R. & Moudgil, B. M.) 211\u2013219 (Humana Press, 2010)."},{"key":"94291_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2022.119221","volume":"1869","author":"S Ebrahimi","year":"2022","unstructured":"Ebrahimi, S., Mirzavi, F., Aghaee-Bakhtiari, S. H. & Hashemy, S. I. SP\/NK1R system regulates carcinogenesis in prostate cancer: Shedding light on the antitumoral function of aprepitant. Biochim. Biophys. Acta (BBA) Mol. Cell Res. 1869, 119221. https:\/\/doi.org\/10.1016\/j.bbamcr.2022.119221 (2022).","journal-title":"Biochim. Biophys. Acta (BBA) Mol. Cell Res."},{"key":"94291_CR53","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/s0076-6879(84)05016-3","volume":"105","author":"H Aebi","year":"1984","unstructured":"Aebi, H. Catalase in vitro. Methods Enzymol. 105, 121\u2013126. https:\/\/doi.org\/10.1016\/s0076-6879(84)05016-3 (1984).","journal-title":"Methods Enzymol."},{"key":"94291_CR54","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3831\/kpi.2018.21.032","volume":"21","author":"F Asgharzadeh","year":"2018","unstructured":"Asgharzadeh, F. et al. Thymoquinone prevents myocardial and perivascular fibrosis induced by chronic lipopolysaccharide exposure in male rats: Thymoquinone and cardiac fibrosis. J. Pharmacopuncture 21, 284\u2013293. https:\/\/doi.org\/10.3831\/kpi.2018.21.032 (2018).","journal-title":"J. Pharmacopuncture"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94291-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94291-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94291-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T22:13:24Z","timestamp":1742595204000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-94291-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["94291"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-94291-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,21]]},"assertion":[{"value":"23 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9798"}}